Kintara Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2010
Net Income	-15.02	-25.13	-41.5	-9.14	-8.13	-11.31	-8.87	-9.1	-4.35	6.36	Upgrade
Depreciation & Amortization	0.06	0.06	0.03	0.01	0.02	0.02	0.02	0.01	0	0	Upgrade
Share-Based Compensation	1.49	2.25	5.28	0.5	0.95	0.54	0.12	0.39	0.19	1.52	Upgrade
Other Operating Activities	1.23	-0.04	14.13	0.69	0.75	0.72	-0.08	3.31	0.31	-11.88	Upgrade
Operating Cash Flow	-11.87	-20.39	-18.86	-7.93	-6.33	-9.85	-8.02	-5.15	-3.85	-4	Upgrade
Capital Expenditures	-0.23	0	-0.01	0	0	-0.01	-0.02	-0.02	0	0	Upgrade
Acquisitions	0	0	0.97	0	0	0	0	0	0	0	Upgrade
Investing Cash Flow	-0.23	0	0.96	0	0	-0.01	-0.02	-0.02	0	0	Upgrade
Share Issuance / Repurchase	1.9	21.57	21.68	6.58	3.36	8.95	8.48	3.03	1.4	2.48	Upgrade
Other Financing Activities	-0.05	0.07	4.37	0.02	0.71	0.3	-0.01	6.53	-0.56	-	Upgrade
Financing Cash Flow	1.85	21.64	26.04	6.6	4.07	9.25	8.47	9.57	0.85	2.48	Upgrade
Net Cash Flow	-10.25	1.24	8.15	-1.33	-2.25	-0.61	0.43	4.4	-3.01	-1.52	Upgrade
Free Cash Flow	-12.1	-20.39	-18.87	-7.93	-6.33	-9.86	-8.04	-5.16	-3.85	-4	Upgrade
Free Cash Flow Per Share	-7.47	-20.94	-36.44	-37.95	-122.88	-236.41	-333.69	-235.77	-202.43	-250.49	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).